secwatch.observer — SEC 8-K summary
======================================

Issuer:     Invivyd, Inc. (IVVD)
CIK:        0001832038
Form:       8-K
Filed at:   2025-06-26T23:59:59+00:00
Accession:  0000950170-25-090172
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Invivyd reports positive Phase 1/2 data for VYD2311 COVID-19 mAb; half-life up to 76 days
--------------------------------------------------------------------------------

- All adverse events mild to moderate; no serious or severe AEs observed across IV, SC, and IM routes.
- VYD2311 half-life by cohort: IM 76 days, high-dose IV 61 days, vs pemivibart's 49 days.
- Dose modeling indicates IM dosing every 3 months may provide robust efficacy for immunocompromised and non-IC.
- Type C meeting with FDA scheduled for early Q3 2025 to discuss registration path for VYD2311.
- VYD2311 is 99%+ structurally identical to adintrevimab and pemivibart, with improved potency.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/0000950170-25-090172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1832038/000095017025090172/ivvd-20250626.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-090172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer